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in Consecutive Patients With Suspected
Acute Coronary Syndrome Who Are Troponin-Negative
Karthik Viswanathan, MD,* Niamh Kilcullen, MD,* Christine Morrell,* Sue J. Thistlethwaite,*
Mohan U. Sivananthan, MD,† Tajek B. Hassan, MD,§ Julian H. Barth, MD,‡
Alistair S. Hall, MD, PHD*
Leeds, United Kingdom
Objectives The purpose of this study was to establish the prognostic value of measuring heart fatty acid-binding protein (H-
FABP) in patients with suspected acute coronary syndrome (ACS) (in particular, low- to intermediate-risk pa-
tients), in addition to troponin measured with the latest third-generation troponin assay.
Background We have previously shown that H-FABP is a useful prognostic marker in patients with proven ACS.
Methods Patients (n  1,080) consecutively admitted to the hospital with suspected ACS were recruited over 46 weeks.
Siemens Advia Ultra-TnI (Siemens Healthcare Diagnostics, Newbury, United Kingdom) and Randox Evidence
H-FABP (Randox Laboratories, Ltd., Co., Antrim, United Kingdom) were analyzed on samples collected 12 to 24 h
from symptom onset. After exclusion of patients with ST-segment elevation and new left bundle branch block,
955 patients were included in the analysis.
Results The primary outcome measure of death or readmission with myocardial infarction after a minimum follow-up
period of 12 months (median 18 months) occurred in 96 of 955 patients (10.1%). The H-FABP concentration
was an independent predictor of death or myocardial infarction, after multivariate adjustment. Patients with
H-FABP concentrations 6.48 g/l had significantly increased risk of adverse events (adjusted hazard ratio:
2.62, 95% confidence interval: 1.30 to 5.28, p  0.007). Among troponin-negative patients (which constituted
79.2% of the cohort), the aforementioned cutoff of 6.48 g/l identified patients at very high risk for adverse
outcomes independent of patient age and serum creatinine.
Conclusions We have demonstrated that the prognostic value of elevated H-FABP is additive to troponin in low- and
intermediate-risk patients with suspected ACS. Other studies suggest that our observations reflect the value of
H-FABP as a marker of myocardial ischemia, even in the absence of frank necrosis. (J Am Coll Cardiol 2010;
55:2590–8) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.062H
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Aeart-type fatty acid-binding protein (H-FABP) is a low-
olecular-weight cytoplasmic protein that is involved in the
ntracellular uptake and buffering of free fatty acids in the
yocardium (1). We have recently demonstrated that
rom the *C-NET Group, Multidisciplinary Cardiovascular Research Centre, The
IGHT Institute, University of Leeds, Leeds, United Kingdom; and the †Depart-
ent of Cardiology, ‡C-NET Group, Department of Clinical Biochemistry, and the
C-NET Group, Department of Emergency Medicine, The General Infirmary at
eeds, Leeds, United Kingdom. Parts of this work were supported by a grant from the
ritish Heart Foundation and free troponin I assays given by Siemens Healthcare
iagnostics. Drs. Hall, Barth, and Sivananthan received grants from the British Heart
oundation and unrestricted grants from Medtronic, Sanofi-Aventis, Pfizer, Siemens
ealthcare diagnostics, and Randox Laboratories to support this research.f
Manuscript received August 13, 2009; revised manuscript received November 30,
009, accepted December 17, 2009.-FABP predicts long-term mortality in a study of 1,448
atients with acute coronary syndrome (ACS) and that this
rediction was independent of the GRACE (Global Reg-
stry of Acute Coronary Events) clinical risk factors, tropo-
in and high-sensitivity C-reactive protein (2). In particu-
ar, H-FABP was able to identify those troponin-negative
atients with unstable angina who were at high risk of
ubsequent death. This observation has been independently
upported by O’Donoghue et al. (3) in their study of 2,287
CS patients recruited in the Thrombolysis In Myocardial
nfarction-16 trial. However, both these studies were per-
ormed on selected patients with independently confirmed
CS. Therefore, they offer predictive information on mortalityor patients with ACS but cannot be used to provide diagnostic
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June 8, 2010:2590–8 H-FABP Predicts Mortality in Suspected ACSnformation, because they did not include consecutive series
ith chest pain; there were not significant numbers of either
troponin-negative” or low- to intermediate-risk patients (4).
his group of apparently low-risk patients is likely to benefit
he most from accurate risk stratification.
Over the past few years, troponin assays have improved,
nd newer assays can now achieve the analytical perfor-
ance spelled out in the Joint European Society of Cardi-
logy/American College of Cardiology consensus document
n redefining myocardial infarction (MI) published in
000—which recommended a coefficient of variation (CV)
f 10% at the 99th percentile value of a reference healthy
opulation (5). There is emerging evidence that these
mprovements increase the early diagnostic and prognostic
alue of the newer troponin assays (6–8). This raises the
uestion of whether there is still additional value in mea-
uring novel markers such as H-FABP in conjunction with
he newer troponin assays (9). To address this, we designed
nd conducted the FAB (Heart-Type Fatty Acid Binding
rotein in Suspected ACS) study, which recruited a con-
ecutive series of patients who presented to hospital with
uspected ACS. Our primary aim was the evaluation of the
omplementary value of H-FABP, particularly for those
atients found to be negative for troponin measured with a
hird-generation troponin assay (Advia Centaur TnI-Ultra,
iemens Healthcare Diagnostics, Newbury, United
ingdom).
ethods
tudy design and patient selection. The study was a
rospective observational study of patients with suspected
CS presenting consecutively to a large teaching hospital in
eeds, United Kingdom. All individuals ages 18 years or
bove with chest pain of possible or definite cardiac etiology
ere deemed eligible for recruitment, irrespective of elec-
rocardiographic (ECG) changes. Individuals presenting
ithout chest pain but with other symptoms suggestive of
CS (dyspnea, diaphoresis, back pain, and so forth) were
lso included, if considered to be compatible with an
typical presentation of ACS by the assessing physician in the
mergency department. We excluded patients: 1) who were
nwilling or unable to provide informed consent; 2) from
hom precisely timed additional blood samples could not be
btained; and 3) who were admitted with an identified non-
ardiac cause of chest pain on presentation (such as pneumonia
r pulmonary embolism). When in doubt, the final judgment
egarding appropriateness of inclusion into the study was made
y the research team (2 specialist cardiology nurses and 1
ardiology research physician) at the time of obtaining written
onsent.
Between May 15, 2006, and April 1, 2007, we enrolled
,080 consenting patients with suspected ACS, who all
rovided informed consent for participation and long-term
ollow-up. Consent was obtained at the earliest opportunity
y the research team together with support from doctors mnd nursing staff working in the
mergency department, as speci-
ed in the study protocol. All
tudy subjects were managed in
ccordance with existing patient
are pathways in the hospital,
hich require all patients with sus-
ected ACS to be admitted either
nder the care of a cardiologist (if
he patient was deemed interme-
iate or high clinical risk) or in the
linical Decisions Unit run by the
mergency department (if the pa-
ient was deemed low-risk) for a
eriod of observation. All indi-
iduals enrolled into the study had additional serum and
lasma samples taken for the purpose of research at the
ame time as the clinical blood sample taken for the
routine” troponin testing—at least 12 h from symptom
nset. Only the “routine” troponin test sample was analyzed
n real time, and the result was made available to the
ttending physician for further clinical management. Con-
equently, participation in the study did not influence the
outine care and immediate/long-term management. Pa-
ients recruited into the study also had an earlier serum
ample collected at the time of first contact with the
mergency department whenever logistically possible. All
dditional research samples collected were centrifuged and
tored in a –70°C freezer within 4 h of venipuncture and
ater analyzed as a single batch.
Most research blood samples collected were timed to
oincide with “routine” venepuncture, carried out by clinical
nd support staff, to ensure little additional inconvenience to
he patients. The study design was intentionally pragmatic,
o as to be readily generalizable to other patients with
uspected ACS as well as to maximize the chances of
oluntary enrolment into the study to ensure that the final
ohort was truly representative of unselected patients with
uspected ACS. Demographic and relevant clinical data
ere collected at the time of consent from patient medical
ecords and patient interview.
All patients were followed up for the occurrence or death
nd/or MI over a minimum period of 12 months. The date
f censorship of follow-up data was April 1, 2008 (median
ollow-up 18 months). Survival status was obtained through
he U.K. Office of National Statistics. We have ensured no
oss to follow-up on mortality data from the Office for
ational Statistics by obtaining data from at least 4 months
fter the date of censorship to allow for lag time from death
o documentation of death. We set out to obtain data on
e-admission to hospital with MI from 2 sources—directly
rom the patients via patient follow-up questionnaires and
rom the hospital electronic records system. The first meth-
dology yielded responses from only 68% of patients, with
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
CV  coefficient of
variation
ECG  electrocardiogram
H-FABP  heart-type fatty
acid-binding protein
HR  hazard ratio
MI  myocardial infarction
TnI  troponin Iany patients expressing ambiguity about the diagnosis of
M
e
w
w
t
i
a
e
L
e
t
s
r
t
L
A
T
a
s
A
r
a
p
c
l
t
0
T
t
c
o
s
A
c
f
t
t
s
1
t
d
w
p
s
a
5
g
S
u
p
C
t
v
w
H
w
s
g
F
s
R
C
s
s

i
c
t
p
b
H
p
p
a
H
w
r
p
A
o
i
t
r
b
fi
9
d
(
o
c
e
r
g
a
w
s
m
c
a
P
T
a
a
b
H
2592 Viswanathan et al. JACC Vol. 55, No. 23, 2010
H-FABP Predicts Mortality in Suspected ACS June 8, 2010:2590–8I. By contrast, the information obtained from the hospital
lectronic records system was robust and reproducible. This
as successfully validated on a random sample of patients
ith patient hospital records and patient follow-up ques-
ionnaires. Therefore, we have used this methodology for
dentification of adverse events of readmission with MI in
ll our analyses. Because our hospital is the sole provider of
mergency care for patients with chest pain in the city of
eeds and the sole provider of primary angioplasty for the
ntire West Yorkshire region, we expect to have identified
he vast majority of recurrent events. A small number of
ilent events and any occurring outside the West Yorkshire
egion might have been missed. This would not be expected
o produce any bias to our results.
aboratory analyses. Troponin was measured with the
dvia Centaur system (Siemens Healthcare Diagnostics).
he assay for measuring troponin in routine clinical practice
t our recruiting hospital was upgraded partway through the
tudy (September 12, 2006), from Advia Troponin I to
dvia TnI-Ultra. However, the troponin value used in
outine clinical practice for classifying patients as having had
n acute MI was effectively unchanged throughout the study
eriod. For the period when Advia Troponin I was used, the
utoff value was set at 0.18 g/l, which represented the
owest concentration at which the CV was 10%. When
he Advia TnI-Ultra was used, the cutoff value used was
.14 g/l, which corresponded to 0.18 g/l for the Advia
roponin I assay (in-house evaluation). For the purpose of
his study and to ensure that all study patients were
ategorized in accordance with the new universal definition
f MI (10), all stored serum samples were analyzed as a
ingle batch at the end of the study, with the highly sensitive
dvia TnI-Ultra assay. We determined the cutoff value
orresponding to the 99th percentile value of healthy adults
or this assay as 0.05 g/l locally (with a reference popula-
ion of 299 healthy adults) and have used this throughout
his report. We also observed that the single batch analysis
howed considerable precision with an intra-assay CV of
0% at a concentration 0.01 g /l for Advia TnI-Ultra.
The H-FABP was measured with the Biochip array
echnology on the fully automated Evidence system (Ran-
ox Laboratories, Ltd., Co., Antrim, United Kingdom)
ith the Cardiac Biochip. This biochip uses a high-
recision, chemiluminescent immunometric assay for mea-
uring H-FABP with 2 mouse monoclonal antibodies. We
ssessed the inter-assay CV to be 5% at a concentration of
.8 g/l (99th percentile values for subjects with estimated
lomerular filtration rate 60 ml/min) (11).
tatistical analyses. Data are presented as mean  SD
nless otherwise stated, and all statistical analyses were
erformed with SPSS software (version 16, SPSS, Inc.,
hicago, Illinois). Groups of patients were compared with
he chi-square test for categorical variables and analysis of
ariance for continuous variables. Event-free survival curves 6ere generated as univariable Kaplan-Meier estimates.
azard ratios (HRs) and 95% confidence intervals (CIs)
ere calculated by constructing first a univariable and
ubsequently a multivariable Cox proportional hazards re-
ression model, with death or MI as the dependent variable.
or all tests, p  0.05 was considered to be statistically
ignificant.
esults
ohort description and long-term outcomes. The FAB
tudy identified 1,080 patients admitted to hospital with
uspected ACS, all of whom had troponin I (TnI) measured
12 h from symptom onset. Approximately one-half of all
ndividuals admitted with suspected ACS during the re-
ruitment period were included in the study. Figure 1 shows
he enrolment of patients into the study. We excluded 97
atients presenting with ST-segment elevation or new left
undle branch block on their ECG and 28 patients in whom
-FABP results were unavailable. The remaining 955
atients were included in the analyses. The mean age of
atients included was 60 15 years; 577 were male (60.5%)
nd 378 were female (39.5%). Advia TnI-Ultra (Siemens
ealthcare Diagnostics) had a non-Gaussian distribution
ith a median concentration of 0.02 g/l (interquartile
ange 0.01 to 0.04 g/l). We classified 199 of 955 (20.8%)
atients as having non–ST-segment elevation MI, with
dvia TnI-Ultra0.05 g/l (as per the Universal definition
f MI). Heart-type fatty acid-binding protein was measured
n all 955 patients. We observed a non-Gaussian distribu-
ion, with a median concentration of 2.42 g/l (interquartile
ange 1.57 to 3.95 g/l). Table 1 provides a summary of the
aseline characteristics across the cohort and further strati-
ed according to H-FABP concentration.
As of April 1, 2008 (median follow-up 18 months), 59 of
55 (6.2%) had died, and the primary outcome measure of
eath or readmission with MI had occurred in 96 of 955
10.1%). Table 2 shows the occurrence of death and death
r MI—hereafter referred to as “events”—across the study
ohort, which has been split into 4 groups on the basis of an
qual number of “events.” There is a gradient of increasing
isk with increasing concentrations of troponin across the 4
roups. It is also notable that the frequency of inpatient
ngiography and revascularization in Groups 1 and 2 (in
hom all patients were deemed troponin “negative”) is
ignificantly lower than in Groups 3 and 4 (where the vast
ajority of patients were deemed troponin “positive”). In
ontrast, the event rate observed increased progressively
cross all groups.
rognostic value of H-FABP across the entire cohort.
able 3 shows the occurrence of “events” (death or MI)
cross the cohort stratified by H-FABP results. For this
nalysis, the entire cohort was split into 4 groups on the
asis of equal number of events as follows: Group 1:
-FABP3.26 g/l, Group 2: 3.27 to 6.48 g/l, Group 3:.49 to 12.77 g/l, Group 4: 12.77 g/l. Patients were
f
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troponin-negative) in accordance with the new Universal
efinition of MI (10), with the cutoff value of troponin
orresponding to the 99th percentile value for healthy adults
i.e., 0.05 g/l). There is a gradient of increasing risk across
ncreasing concentrations of H-FABP (p  0.001), irre-
pective of the associated troponin result. Unadjusted HRs
or patients in Groups 3 and 4 according to H-FABP
oncentration (as shown in Table 4) were 15.67 (95% CI:
.16 to 30.07) and 20.37 (95% CI: 10.38 to 40.00),
espectively (both p  0.001), compared with Group 1.
igure 2 shows the corresponding Kaplan-Meier event-free
urvival curves for the 4 groups according to H-FABP
oncentration. Table 4 summarizes the findings of the
Figure 1 Enrollment of Patients Into the Study
Flowchart shows patient enrolment into the study. TnI-Ultra (Siemens Healthcare D
ACS  acute coronary syndrome; H-FABP  heart-type fatty acid-binding protein; Lnivariate analyses that were performed to assess the mag- nitude of risk (death or MI at median follow-up of 18
onths) associated with various baseline risk factors that
ere statistically significant across the 4 groups of H-FABP
Table 1). All factors that were significantly associated with
isk on univariate analysis were then included in a Cox
roportional hazards regression model, and the results of
his multivariable analysis are shown in Table 4. The results
how that age, previous MI, admission heart rate, and
-FABP concentration remained statistically significant as
ndependent predictors of long-term risk. Patients with
-FABP concentrations in Group 3 (6.49 to 12.77 g/l)
ad a significantly increased risk of adverse events with an
djusted HR of 2.62 (95% CI: 1.30 to 5.28, p  0.007),
ith Group 4 (12.77 g/l) showing a statistically nonsig-
tics, Newbury, United Kingdom).
left bundle branch block.iagnos
BBB ificant increase in risk with an adjusted HR of 1.54 (95%
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urves comparing the value of H-FABP and TnI in pre-
icting long-term adverse events showed H-FABP to be
omparable to TnI (area under the curve for H-FABP 
.79 [95% CI: 0.74 to 0.84] vs. TnI  0.77 [95% CI: 0.72
o 0.82]), as shown in Figure 3.
rognostic value of H-FABP in the TnI-negative sub-
roup. In the troponin-negative subgroup (n  756), there
ere 40 major adverse events (death or MI) during the
ollow-up period. Table 3 shows the event rate across each
f the 4 groups on the basis of H-FABP concentrations as
escribed in the earlier section. Table 5 shows the unad-
usted HRs for troponin-negative patients, after stratifying
atients into the same 4 groups. This shows increasing risk
n Groups 2, 3, and 4 as compared with Group 1 with a very
ignificantly increased event rate in patients with H-FABP
oncentrations above 6.48 g/l (Groups 3 and 4)—
nadjusted HR in Group 3: 11.20 (95% CI: 4.95 to 25.36),
 0.001. Table 5 shows the adjusted HRs after adjust-
ent for age and serum creatinine in a Cox proportional
azards regression model. This confirms the additional
rognostic value of H-FABP 6.48 g/l (adjusted HR:
.12, 95% CI: 1.11 to 8.76, p  0.03), independent of age
nd serum creatinine.
aseline Characteristics According to H-FABP Groups by Equal NumTable 1 Baseline Characteristics According to H-FABP Groups
Entire Cohort
(Events  96 of n  955)
H-FABP Group 1
<3.26 g/l
(Events  24 of n  635)
Age, yrs (SD) 60.01 (15.00) 55.44 (13.99)
Male sex 60.5% 59.9%
Diabetes 15.1% 11.3%
Smoking 24.4% 25.8%
Hypertension 61.2% 40.7%
Family history of CAD 55.0% 57.4%
Previous MI 30.5% 22.4%
Prior PCI/CABG 23.3% 19.8%
Previous heart failure 5.1% 2.2%
ST-segment depression on ECG 10.6% 4.9%
Creatinine, mg/dl (SD) 1.14 (0.30) 1.06 (0.16)
Systolic BP, mm Hg (SD) 138.01 (25.41) 136.29 (22.67)
Heart rate, beats/min (SD) 77.59 (20.39) 75.05 (17.15)
Troponin-negative0.05 g/l 79.2% 90.2%
P  blood pressure; CABG  coronary artery bypass grafting; CAD  coronary artery disease; E
ercutaneous coronary intervention; Q  quartile.
anagement and Long-Term Outcomes on the Basis of Troponin ReTable 2 Management and Long-Term Outcomes on the Basis o
Entire Cohort
(n  955)
TnI Group 1
0.00–0.02 g/l
(Events  24 of n  641)
Tn
0.03
(Events 
Inpatient angiogram 15.4% (147) 6.1% (39) 8
Inpatient PCI/CABG 8.1% (77) 1.4% (9) 2
Death 6.2% (59) 2.7% (17) 9
Death or MI 10.1% (96) 3.7% (24) 16nI  Troponin I; other abbreviations as in Table 1.iscussion
espite enormous research interest in cardiac biomarkers in
ecent years, very few have established themselves unequiv-
cally in routine clinical practice. Cardiac troponin remains
he cornerstone in the risk stratification of patients with
uspected ACS. One of the important criteria for a biomar-
er is to be able to inform clinical decision-making and thus
nfluence patient management (12). Heart-type fatty acid-
inding protein has emerged as an independent prognostic
arker for patients with ACS in at least 2 large studies
2,3). The FAB study was specifically designed to comple-
ent our earlier study on H-FABP (2) and extend the
pplicability of the results to contemporary clinical practice
y including low-risk subjects. Our study population (ex-
luding those presenting with ST-segment elevation or new
eft bundle branch block) included 79.2% of subjects with
nI below the 99th percentile, which is consistent with
everal routine laboratory audits. In this first report resulting
rom the FAB study, we have confirmed our previous
nding for patients with proven ACS—that H-FABP
dentifies high-risk patients who are troponin-negative.
Since the publication of the New Definition of MI in
000 (5), there have been few studies reporting long-term
ajor adverse outcomes (death, MI) for a large consecutive
of Eventsual Number of Events
-FABP Group 2
.27–6.48 g/l
ts  24 of n  203)
H-FABP Group 3
6.49–12.77 g/l
(Events  24 of n  63)
H-FABP Group 4
>12.78 g/l
(Events  24 of n  54) p Value
67.37 (12.22) 72.03 (11.26) 71.93 (14.71) 0.001
58.6% 68.3% 64.8% 0.50 (NS)
23.3% 22.6% 19.6% 0.001
20.2% 21.7% 26.9% 0.40 (NS)
67.0% 71.0% 61.2% 0.001
51.5% 42.0% 53.2% 0.13 (NS)
40.3% 65.1% 47.2% 0.001
30.7% 33.9% 24.5% 0.003
8.1% 10.9% 23.4% 0.001
15.3% 23.8% 44.4% 0.001
1.22 (0.27) 1.36 (0.30) 1.54 (0.71) 0.001
40.98 (27.47) 133.92 (29.13) 152.45 (36.89) 0.001
80.98 (23.47) 82.63 (29.05) 88.74 (24.49) 0.001
72.9% 50.8% 5.6% 0.001
lectrocardiogram; H-FABP  heart-fatty acid-binding protein; MI  myocardial infarction; PCI 
onin Results
p 2
g/l
f n  146)
TnI Group 3
0.09–3.04 g/l
(Events  24 of n  99)
TnI Group 4
>3.04 g/l
(Events  24 of n  69) p Value
2) 49.5% (49) 68.1% (47) 0.001
) 33.3% (33) 46.4% (32) 0.001
4) 12.1% (12) 23.2% (16) 0.001
4) 24.2% (24) 34.8% (24) 0.001berby Eq
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June 8, 2010:2590–8 H-FABP Predicts Mortality in Suspected ACSopulation of patients presenting with chest pain/suspected
CS (13–15). In keeping with these published studies, the
ajority of our subjects were at low-to-intermediate risk.
umber of Major Adverse Events Across the 4 Subgroups on theasis of H-FABP Concentratio s and Stratified by Troponin ResultsTable 3 Number of Major Adverse Events Across the 4 SubgrouBasis of H-FABP Concentrations and Stratified by Trop
H-FABP Concentration
“Not MI” According t
(Troponin <
Group 1  0.15–3.26 g/l (events  24 of n  635) 16/573
Group 2  3.27–6.48 g/l (events  24 of n  203) 14/148
Group 3  6.49–12.77 g/l (events  24 of n  63) 9/32
Group 4  12.78–151.00 g/l (events  24 of n  54) 1/3
Entire cohort (N  955) 40/756
p value 0.
ajor adverse events are death or MI after a median follow-up period of 18 months.
Abbreviations as in Table 2.
Rs for Death or MI After Medianollow-Up Period of 18 MonthsTable 4 HRs for Death or MI After MedianFollow-Up Period of 18 Months
Univariate* HR (95% CI) p Value
Age 1.11 (1.08–1.12) 0.001
Diabetes 2.43 (1.48–3.99) 0.001
Hypertension 1.95 (1.25–3.05) 0.003
Previous PCI/CABG 1.64 (1.03–2.61) 0.043
Previous heart failure 5.62 (2.89–10.96) 0.001
Previous MI 4.60 (2.94–7.18) 0.001
Heart rate 1.024 (1.015–1.033) 0.001
Systolic BP 1.005 (0.97–1.014) 0.21
ST-segment depression on ECG 6.48 (3.98–10.55) 0.001
Creatinine 1.025 (1.018–1.033) 0.001
TnI 0.00–0.02 g/l 1.00 0.001
TnI 0.03–0.08 g/l 5.06(2.78–9.20) 0.001
TnI 0.09–3.04 g/l 8.22 (4.55–15.2) 0.001
TnI 3.04 g/l 13.71 (7.22–26.05) 0.001
H-FABP 0.15–3.26 g/l 1.00 0.001
H-FABP 3.27–6.48 g/l 3.41 (1.89–6.16) 0.001
H-FABP 6.49–12.77 g/l 15.67 (8.16–30.07) 0.001
H-FABP 12.78–151.0 g/l 20.37 (10.38–40.00) 0.001
Multivariable†
Age 1.06 (1.03–1.08) 0.001
Diabetes 1.67 (0.97–2.87) 0.062
Hypertension 1.06 (0.65–1.73) 0.81
Prior heart failure 1.29 (0.65–2.56) 0.47
Prior MI 1.79 (1.08–2.98) 0.025
Heart rate 1.01 (1.00–1.02) 0.004
ST-segment depression on ECG 1.73 (0.98–3.05) 0.59
Creatinine 1.00 (0.99–1.01) 0.48
TnI 0.00–0.02 g/l 1.00 0.10
TnI 0.03–0.08 g/l 2.15 (1.11–4.17) 0.024
TnI 0.09–3.04 g/l 2.09 (1.01–4.36) 0.048
TnI 3.04 g/l 2.41 (0.95–6.09) 0.063
H-FABP 0.15–3.26 g/l 1.00 0.003
H-FABP 3.27–6.48 g/l 0.78 (0.39–1.55) 0.48
H-FABP 6.49–12.77 g/l 2.62 (1.30–5.28) 0.007
H-FABP 12.78–151.0 g/l 1.54 (0.55–4.32) 0.41
Unadjusted univariate analysis; †multivariate analysis including all factors noted to be significant
n univariate analysis (except previous PCI/CABG in view of borderline significance only on
nivariate analysis).
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 2.onsequently, we note significantly lower occurrence of
eath and MI compared with previously published studies
n H-FABP that largely included high-risk ACS patients.
he event rate in our study was slightly lower than the
onsecutive chest pain population studies mentioned earlier.
his is consistent with global improvement in care of
atients with ACS secondary to the increasing use of
vidence-based pharmacological therapy (aspirin, clopi-
ogrel, statin, beta-blocker, ACE inhibitor) and coronary
ntervention.
Recently, McCann et al. (16) reported on the prognostic
alue of H-FABP among other markers in 664 patients
resenting to coronary care unit with ischemic-type chest
ain recruited over 3 years. The authors showed that
-FABP and N-terminal pro–B-type natriuretic peptide
ad independent prognostic value in addition to troponin.
ur study confirms the long-term prognostic value of
-FABP demonstrated in this and earlier studies (2,3) in a
Figure 2
Kaplan Meier Event-Free Survival Curves
for Death or MI in the 4 Groups of Patients
on the Basis of H-FABP Concentrations
Each curve represents a subgroup of patients defined by the measured con-
centration of heart-type fatty acid-binding protein (H-FABP). Group 1: H-FABP
3.26 g/l, Group 2: 3.27 to 6.48 g/l, Group 3: 6.49 to 12.77 g/l, Group
4: 12.77 g/l. For hazard ratios for each of the groups, see Table 4. MI 
myocardial infarction.
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H-FABP Predicts Mortality in Suspected ACS June 8, 2010:2590–8arger and unselected consecutive cohort of suspected ACS
atients. We have shown that the risk of death or recurrent
I increases with increasing concentrations of H-FABP
ith a significant increase in patients with H-FABP 6.48
g/l, and this is independent of other established clinical
isk factors, including troponin. One of the particular
trengths of studying an unselected cohort of consecutive
atients with suspected ACS (as in our study) is that the
esults can be extrapolated more readily to contemporary
linical practice. Therefore, we believe that this takes us 1
tep closer toward establishing the clinical utility of routine
easurement of H-FABP in suspected ACS.
The ideal cutoff value for defining troponin positivity in
uspected ACS has been long identified as the 99th percen-
ile value in a population of healthy adults, and this has been
einforced in the more recently published Universal Defini-
ion of Myocardial Infarction (10). However, the fact that
o commercially available assays were able to achieve the
tandard of a CV 10% at the 99th percentile value until
ecently has remained a major limitation (17). Therefore, it
as likely that before 2008 some patients were misclassified
s low-risk, thus overestimating the magnitude of benefit of
iomarkers studied in conjunction with troponin. In this
tudy, we measured troponin with the ultra-sensitive TnI-
ltra (Siemens Healthcare Diagnostics) assay, a third-
eneration troponin assay that satisfies the requirements
tated in the Universal Definition of MI (10). It is notable
hat the independent prognostic value of H-FABP demon-
trated in patients with suspected ACS is not negated by the
se of the newer ultra-sensitive troponin assays.
We have demonstrated, in particular, that the long-term
rognostic value of H-FABP in troponin-negative patients
Figure 3 Receiver-Operator Curves for H-FABP
and TnI-Ultra in the Prediction of Death or MI
Receiver-operator curves for H-FABP and troponin I (TnI) in prediction of death
or MI after median of 18 months follow-up. Area under the curve for H-FABP 
0.79 (95% confidence interval 0.74 to 0.84). Area under the curve for TnI 
0.77 (95% confidence interval: 0.72 to 0.82). Abbreviations as in Figures 1
and 2.s independent of age and serum creatinine, both of which Aave been shown to influence H-FABP concentrations in
pparently healthy subjects (11). Our study suggests that
roponin-negative patients with H-FABP 6.48 g/l rep-
esent a very-high-risk group of patients, and we suggest
hat further investigations such as coronary angiography and
ppropriate pharmacotherapy are warranted in this small
ubgroup of patients (35 of 756, 4.6% of all troponin-
egative patients in our study).
In a recent publication by our group, we have defined the
9th percentile values for H-FABP measured with 2 com-
ercially available assays in a population of primary and
econdary care outpatients (11). The 99th percentile values
or subjects with estimated glomerular filtration rate 60
l/min for the Evidence Investigator H-FABP assay used
n this study were 5.3 and 5.8 g/l in female and male
ubjects, respectively. In our present study, with this cutoff
alue to define patients as “elevated H-FABP,” these
atients had significantly increased event rate. The unad-
usted HRs for death or MI for those with “elevated
-FABP” as defined by this cut-off value were 3.70 (95%
I: 1.82 to 7.56, p  0.0001) in troponin-positive patients
nd 6.57 (95% CI: 3.05 to 14.11, p  0.0001) among
roponin-negative patients.
We acknowledge a few limitations of this study. It must
e noted that 53.2% of eligible patients admitted during the
eriod of recruitment were enrolled into the main study.
his was largely because, although patients with suspected
CS present 24 h/day and 7 days/week, participation in a
tudy of this nature requires informed consent and precisely
imed sample collection within a few hours of hospital
dmission—making the study logistically quite challenging.
he exclusion of patients from the study (Fig. 1) was
andom, and we believe that this was unlikely to introduce
ny systematic bias to our results. We also note the
imitations inherent to any statistical modeling and multi-
ariate adjustment. Although we only included the most
mportant clinical variables likely to cause confounding
uring statistical modeling, we recognize the potential for
ver-fitting of the statistical model. However, we note that
n usual clinical care it is rare for diagnostic tests to be used
n any other than the unadjusted form.
Rs for Death or MI Stratified by H-FABPe ults Among Troponin-Negative PatientsTable 5 HRs f r Death or MI Str tified by H-FABPResults Among Troponin-Negative Patients
Unadjusted HR (95% CI) p Value
H-FABP 0.15–3.26 g/l 1.00 0.001
H-FABP 3.27–6.48 g/l 3.46 (1.69–7.10) 0.001
H-FABP 6.49–12.77 g/l 11.20 (4.95–25.36) 0.001
H-FABP 12.78–151.0 g/l 16.64 (2.21–125.51) 0.006
Adjusted for Age and Serum Creatinine Adjusted HR (95% CI)
H-FABP 0.15–3.26 g/l 1.00 0.01
H-FABP 3.27–6.48 g/l 1.55 (0.72–3.36) 0.26
H-FABP 6.49–12.77 g/l 3.12 (1.11–8.76) 0.03
H-FABP 12.78–151.0 g/l 16.67 (2.19–127.06) 0.007bbreviations as in Tables 1 and 4.
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June 8, 2010:2590–8 H-FABP Predicts Mortality in Suspected ACSWe report here results for biomarkers measured at only 1
ime-point (i.e., 12 h from symptom onset). This was our
re-stated objective and is in keeping with standard practice
n our institution and indeed most other hospitals in the
nited Kingdom. Initial risk stratification of patients into
igh and low risk was done primarily on the basis of clinical
nd ECG parameters rather than admission biomarker
ssessment. The likelihood of a false negative troponin in
ur study is very low, because of the high precision of the
ltra-TnI (Siemens Healthcare Diagnostics) when run in a
ingle batch. Patients recruited into the study also had an
arlier serum sample collected at the time of first contact
ith the emergency department whenever logistically pos-
ible. Future analyses will assess the value of H-FABP (and
ther cardiac markers) measured at this earlier time point in
he early diagnosis of MI in detail. Limited analyses of the
84 troponin-negative patients who had an admission
erum sample collected (of the 756 troponin-negative pa-
ients in the study [i.e., 50%]) showed that the occurrence of
eath or MI among those with raised H-FABP at the time
f admission (male 5.8 g/dl, female 5.3 g/dl) was
2.2% (6 of 27 patients) as compared with a much lower
vent rate of 5.3% in patients with normal H-FABP at
dmission (19 of 357 patients), which was statistically
ignificant (p  0.001) (HR: 5.08, 95% CI: 1.84 to 14.07,
 0.002).
We also note the substantial influence of the troponin
esults in deciding further management, as illustrated by the
ery low rate of inpatient coronary angiography in troponin-
egative patients (Table 2). This underlines the importance
f using the new ultra-sensitive troponin assays and classi-
ying all patients with troponin values 99th percentile
alue as potentially high risk. Importantly, many centers
round the world have yet to make this change, and our data
ndicate that this would be improved further by the parallel
easurement of H-FABP with a similarly high-precision,
igh-sensitivity assay. The multimarker cardiac biochip that
e used in this study (Randox Laboratories, Ltd.) permits
uch parallel measurements to be easily made. Furthermore,
he recent development of a point-of-care platform permits
apid delivery of results and repeat measurements. Further
tudies will assess the value of this system in the context of
uspected ACS and also in the detection of myocardial
schemia and injury in other contexts, such as after PCI or
urgical intervention.
The H-FABP seems to provide direct evidence of myo-
ardial ischemia even when frank myocyte necrosis is absent
18,19). Meng et al. (18) demonstrated that in rats the
-FABP concentration in peripheral blood was 4 times the
aseline after just 15 min of induced myocardial ischemia.
dditionally, in human autopsy cases it was possible to
emonstrate depletion of H-FABP in the myocardium of
ndividuals dying suddenly after the onset of chest pain.
hese changes were present despite the absence of myocyte
ecrosis on electron microscopy (19). This caused thosenvestigators to conclude that H-FABP is both a sensitivend an early marker of myocardial ischemia. Such a conclu-
ion is intuitive, given that H-FABP is confined to the
ytoplasm and also because of its small molecular size,
ecause both these features permit early leakage through the
orous membranes of ischemic myocardial cells. This might
xplain the strong correlation between H-FABP and ST-
egment depression noted on ECG (Table 1). The presence
f myocardial ischemia resulting in chest pain might result
rom coronary spasm in the presence of atheroma but in the
bsence of plaque erosion/rupture and thrombus formation.
uch patients might be expected to have no detectable
roponin and yet have an elevated H-FABP and, impor-
antly, an increased risk of future major cardiovascular event.
onclusions
e have demonstrated that the prognostic value of elevated
-FABP is additive to troponin in low- and intermediate-
isk patients with suspected ACS. Importantly, this is true
n spite of use of a very-high-sensitivity troponin assay that
chieves the analytical performance prescribed in the Univer-
al Definition of MI consensus document (10). We interpret
his as supporting the role of H-FABP as a marker of
yocardial ischemia, even in the absence of frank necrosis.
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